Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Long-term safety and effectiveness of darunavir].
Rubio R, Matarranz M, Bisbal O, de Lagarde M, Domínguez L. Rubio R, et al. Enferm Infecc Microbiol Clin. 2016 May;34 Suppl 1:16-22. doi: 10.1016/S0213-005X(17)30004-6. Enferm Infecc Microbiol Clin. 2016. PMID: 28081758 Review. Spanish. No abstract available.
Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients.
Domínguez-Domínguez L, Lagarde M, Bisbal O, Matarranz M, Rubio R, Pulido F. Domínguez-Domínguez L, et al. Among authors: rubio r. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jun-Jul;38(6):275-278. doi: 10.1016/j.eimc.2019.07.009. Epub 2019 Oct 24. Enferm Infecc Microbiol Clin (Engl Ed). 2020. PMID: 31668860 English, Spanish.
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. AIDS Res Ther. 2020 Jul 20;17(1):45. doi: 10.1186/s12981-020-00302-2. AIDS Res Ther. 2020. PMID: 32690099 Free PMC article.
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
Rial-Crestelo D, de Miguel R, Montejano R, Dominguez-Dominguez L, Aranguren-Rivas P, Esteban-Cantos A, Bisbal O, Santacreu-Guerrero M, Garcia-Alvarez M, Alejos B, Hernando A, Bermejo-Plaza L, Cadiñanos J, Mayoral M, Castro JM, Moreno V, Martin-Carbonero L, Delgado R, Rubio R, Pulido F, Arribas JR; ART-PRO; PI16/00837-PI16/00678 study group. Rial-Crestelo D, et al. Among authors: rubio r. J Antimicrob Chemother. 2021 Feb 11;76(3):738-742. doi: 10.1093/jac/dkaa479. J Antimicrob Chemother. 2021. PMID: 33200210 Clinical Trial.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
895 results